Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is devel... Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer. Mehr anzeigen
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset PR Newswire SAN JOSE, Calif., Nov. 22, 2024 SAN JOSE, Calif., Nov. 22, 2024 /PRNewswire/ -- Anixa...
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif., Nov. 18, 2024 Third cohort dose is one million CAR positive cells; ten...
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting PR...
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting PR...
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 PR Newswire SAN JOSE, Calif., Oct. 31, 2024 SAN JOSE, Calif., Oct. 31, 2024 /PRNewswire/...
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire SAN...
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif., Oct. 15, 2024 Patient showed clinical activity after initial...
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development PR Newswire SAN JOSE, Calif., Oct. 7, 2024 SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.12 | -3.56083086053 | 3.37 | 3.46 | 3.14 | 67290 | 3.26013739 | CS |
| 4 | -0.2 | -5.79710144928 | 3.45 | 4.2 | 3.02 | 150714 | 3.25168931 | CS |
| 12 | 0.08 | 2.52365930599 | 3.17 | 4.2 | 2.93 | 96552 | 3.34476983 | CS |
| 26 | 0.82 | 33.7448559671 | 2.43 | 4.2 | 2.16 | 97917 | 3.12350818 | CS |
| 52 | -0.05 | -1.51515151515 | 3.3 | 5.13 | 2.16 | 131842 | 3.55028285 | CS |
| 156 | 0 | 0 | 3.25 | 6.45 | 2.16 | 97354 | 3.68621599 | CS |
| 260 | -0.47 | -12.6344086022 | 3.72 | 8.09 | 1.33 | 193905 | 3.74567555 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
